Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

PURPOSE: The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in lymphodepleted hosts mediated objective res...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dudley, Mark E., Yang, James C., Sherry, Richard, Hughes, Marybeth S., Royal, Richard, Kammula, Udai, Robbins, Paul F., Huang, JianPing, Citrin, Deborah E., Leitman, Susan F., Wunderlich, John, Restifo, Nicholas P., Thomasian, Armen, Downey, Stephanie G., Smith, Franz O., Klapper, Jacob, Morton, Kathleen, Laurencot, Carolyn, White, Donald E., Rosenberg, Steven A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2008
Materias:
Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652090/
https://ncbi.nlm.nih.gov/pubmed/18809613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.5449
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares